Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases

Cosco, Donato; Paolino, Donatella; Cilurzo, Felisa; Casale, F.; Fresta, Massimo

doi:10.1016/j.ijpharm.2011.10.056

Cited by 79 publications

(30 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specifically, paclitaxel increased the leukosomes’ surface charge to 15 mV. As previously shown for other hydrophobic drugs 38 , paclitaxel intercalates among the hydrophobic tails of the lipid bilayer which likely induced a structural rearrangement of the membrane, possibly through the exposure of the choline groups to the outer bilayer surface 39 . Additionally, a first-order kinetic release profile was observed for DXM and caffeine (Fig.…”

Section: Pharmaceutical Features Of Leukosomesmentioning

confidence: 52%

Biomimetic proteolipid vesicles for targeting inflamed tissues

et al. 2016

View full text Add to dashboard Cite

A multitude of micro- and nanoparticles have been developed to improve the delivery of systemically administered pharmaceuticals, which are subject to a number of biological barriers that limit their optimal biodistribution. Bioinspired drug-delivery carriers formulated by bottom-up or top-down strategies have emerged as an alternative approach to evade the mononuclear phagocytic system and facilitate the transport across the endothelial vessel wall. Here, we describe a method that leverages the advantages of bottom-up and top-down strategies to incorporate proteins derived from the leukocyte plasma membrane into lipid nanoparticles. The resulting proteolipid vesicles - which we refer to as leukosomes - retained the versatility and physicochemical properties typical of liposomal formulations, preferentially targeted inflamed vasculature, enabled the selective and effective delivery of dexamethasone to inflamed tissues, and reduced phlogosis in a localized model of inflammation.

show abstract

Section: Pharmaceutical Features Of Leukosomesmentioning

confidence: 52%

Biomimetic proteolipid vesicles for targeting inflamed tissues

et al. 2016

View full text Add to dashboard Cite

show abstract

“…DLS was further used to measure the polydispersity index (PDI) of the particle distribution. PDI is a measure of breadth of the distribution with PDI < 0.4 for a narrow size distribution, and >0.4 for a broad distribution of particles (Cosco et al, 2012; Paolino et al, 2013). …”

Section: Methodsmentioning

confidence: 99%

Detection and Physicochemical Characterization of Membrane Vesicles (MVs) of Lactobacillus reuteri DSM 17938

et al. 2017

View full text Add to dashboard Cite

Membrane vesicles (MVs) are bilayer structures which bleb from bacteria, and are important in trafficking biomolecules to other bacteria or host cells. There are few data about MVs produced by the Gram-positive commensal-derived probiotic Lactobacillus reuteri; however, MVs from this species may have potential therapeutic benefit. The aim of this study was to detect and characterize MVs produced from biofilm (bMVs), and planktonic (pMVs) phenotypes of L. reuteri DSM 17938. MVs were analyzed for structure and physicochemical characterization by Scanning Electron Microscope (SEM) and Dynamic Light Scattering (DLS). Their composition was interrogated using various digestive enzyme treatments and subsequent Transmission Electron Microscopy (TEM) analysis. eDNA (extracellular DNA) was detected and quantified using PicoGreen. We found that planktonic and biofilm of L. reuteri cultures generated MVs with a broad size distribution. Our data also showed that eDNA was associated with pMVs and bMVs (eMVsDNA). DNase I treatment demonstrated no modifications of MVs, suggesting that an eDNA-MVs complex protected the eMVsDNA. Proteinase K and Phospholipase C treatments modified the structure of MVs, showing that lipids and proteins are important structural components of L. reuteri MVs. The biological composition and the physicochemical characterization of MVs generated by the probiotic L. reuteri may represent a starting point for future applications in the development of vesicles-based therapeutic systems.

show abstract

“…In addition, a study involving co-encapsulation of combretastatin A-4 (vascular disrupting agent) and doxorubicin (anticancer agent) suggested that a combinatorial strategy focused on arginyl-glycylaspartic acid (RGD) mediated delivery of drugs may be a promising strategy for cancer treatment [147]. Another ‘mix and match’ combinatorial treatment regimen involving a multidrug carrier (MDC) containing both gemcitabine and tamoxifen for the treatment of breast cancer has also shown good therapeutic potential [148]. …”

Section: Use Of Nanotechnology To Develop Mtismentioning

confidence: 99%

Use of Nanotechnology to Develop Multi-Drug Inhibitors for Cancer Therapy

Gowda¹,

Jones

Banerjee³

et al. 2013

J Nanomed Nanotechnol

View full text Add to dashboard Cite

Therapeutic agents that inhibit a single target often cannot combat a multifactorial disease such as cancer. Thus, multi-target inhibitors (MTIs) are needed to circumvent complications such as the development of resistance. There are two predominant types of MTIs, (a) single drug inhibitor (SDIs) that affect multiple pathways simultaneously, and (b) combinatorial agents or multi-drug inhibitors (MDIs) that inhibit multiple pathways. Single agent multi-target kinase inhibitors are amongst the most prominent class of compounds belonging to the former, whereas the latter includes many different classes of combinatorial agents that have been used to achieve synergistic efficacy against cancer. Safe delivery and accumulation at the tumor site is of paramount importance for MTIs because inhibition of multiple key signaling pathways has the potential to lead to systemic toxicity. For this reason, the development of drug delivery mechanisms using nanotechnology is preferable in order to ensure that the MDIs accumulate in the tumor vasculature, thereby increasing efficacy and minimizing off-target and systemic side effects. This review will discuss how nanotechnology can be used for the development of MTIs for cancer therapy and also it concludes with a discussion of the future of nanoparticle-based MTIs as well as the continuing obstacles being faced during the development of these unique agents.’

show abstract

Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases

Cited by 79 publications

References 23 publications

Biomimetic proteolipid vesicles for targeting inflamed tissues

Biomimetic proteolipid vesicles for targeting inflamed tissues

Detection and Physicochemical Characterization of Membrane Vesicles (MVs) of Lactobacillus reuteri DSM 17938

Use of Nanotechnology to Develop Multi-Drug Inhibitors for Cancer Therapy

Contact Info

Product

Resources

About